Adrián Mosquera Orgueira discussed AI’s role in hematology decision-making. He noted AI will grow in clinical use but its pace remains uncertain. AI has proven useful in prognostic modeling and risk stratification for myelofibrosis. A machine learning model improved adverse outcome identification in over 5,000 patients. He emphasized AI must be applicable, accessible, and actionable in practice. Generative AI could improve access to specialized medical knowledge. He warned of automation bias eroding clinical reasoning. Prospective validation studies are scarce but needed to confirm clinical benefit. Longitudinal AI models could track evolving patient trajectories. He stressed rigorous regulatory oversight for clinical AI systems.